SCHEMBL5954468

SCHEMBL5954468

CCOC(=O)C(CC)Nc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
LMNA P02545 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
PPARG P37231 1/20 0.56
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPC1 O15118 4/20 0.54
LTA4H P09960 2/20 0.53
NR1H4 Q96RI1 1/20 0.52
AR P10275 1/20 0.51
NOX1 Q9Y5S8 1/20 0.51
GBA1 P04062 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5954359 0.90 ALDH1A1 (0.59) ALDH1A1LMNAL3MBTL1PPARGRAB9A
SCHEMBL6715971 0.88 PPARG (0.63) ALDH1A1LMNAL3MBTL1PPARGRAB9A
SCHEMBL6719959 0.87 ALDH1A1 (0.64) ALDH1A1LMNAL3MBTL1PPARGRAB9A
SCHEMBL5955251 0.86 LMNA (0.66) ALDH1A1LMNAL3MBTL1RAB9ASMN1; SMN2
SCHEMBL5955247 0.86 LMNA (0.66) ALDH1A1LMNAL3MBTL1RAB9ASMN1; SMN2
SCHEMBL5955118 0.84 HPGD (0.61) ALDH1A1LMNAPPARGRAB9ASMN1; SMN2
SCHEMBL5339626 0.79 CA12 (0.52) ALDH1A1L3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL9483448 0.79 RAB9A (0.76) ALDH1A1RAB9ASMN1; SMN2NPC1LTA4H
SCHEMBL25093130 0.78 PPARG (0.60) ALDH1A1LMNAL3MBTL1PPARGRAB9A
SCHEMBL4425843 0.77 L3MBTL1 (0.73) ALDH1A1LMNAL3MBTL1PPARGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 ALDH1A1 452/4885LMNA 3718/4885L3MBTL1 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.